Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes.

Cox SL.

Drugs Today (Barc). 2004 Jul;40(7):633-43. Review.

PMID:
15510236
2.

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

Fonseca V, Rosenstock J, Patwardhan R, Salzman A.

JAMA. 2000 Apr 5;283(13):1695-702. Erratum in: JAMA 2000 Sep 20;284(11):1384.

PMID:
10755495
3.
4.

Sitagliptin: a novel drug for the treatment of type 2 diabetes.

Choy M, Lam S.

Cardiol Rev. 2007 Sep-Oct;15(5):264-71. Review.

PMID:
17700385
5.

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.

PMID:
16291411
6.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
7.

Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.

Hällsten K, Virtanen KA, Lönnqvist F, Sipilä H, Oksanen A, Viljanen T, Rönnemaa T, Viikari J, Knuuti J, Nuutila P.

Diabetes. 2002 Dec;51(12):3479-85.

8.

Rosiglitazone/Metformin.

Wellington K.

Drugs. 2005;65(11):1581-92; discussion 1593-4. Review.

PMID:
16033298
9.
10.

Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.

Kadoglou NP, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD, Sailer N.

Exp Clin Endocrinol Diabetes. 2011 Feb;119(2):63-8. doi: 10.1055/s-0030-1265174. Epub 2010 Oct 28.

PMID:
21031343
11.

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.

Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.

Pharmacotherapy. 2005 May;25(5):637-45.

PMID:
15899724
12.
13.
14.

Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.

Strowig SM, Raskin P.

Diabetes Obes Metab. 2005 Nov;7(6):633-41. Review.

PMID:
16219007
16.

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.

PMID:
16505505
17.

Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.

Derosa G, Tinelli C, Maffioli P.

Diabetes Obes Metab. 2009 Dec;11(12):1091-9. doi: 10.1111/j.1463-1326.2009.01087.x. Epub 2009 Sep 17. Review.

PMID:
19765050
19.

Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.

Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M.

Exp Clin Endocrinol Diabetes. 2008 Jan;116(1):6-13. Epub 2007 Dec 20.

PMID:
18095238
20.

Rosiglitazone : a review of its use in type 2 diabetes mellitus.

Deeks ED, Keam SJ.

Drugs. 2007;67(18):2747-79. Review.

PMID:
18062722

Supplemental Content

Support Center